King's College London

A new treatment for severe asthma and COPD attacks, an injection, has been found more effective than steroid tablets, reducing further treatment needs by 30%, marking the first breakthrough in 50 years.

Benralizumab injection during asthma and COPD attacks reduces need for further treatment by 30%, outperforming steroid tablets, according to a study in The Lancet Respiratory Medicine.

A clinical trial of benralizumab, the first new asthma treatment in 50 years, showed it was more effective than steroids at treating severe asthma attacks, reducing symptoms and improving quality of life. The drug targets white blood cells causing airway swelling in eosinophilic asthma, which accounts for half of all emergency flare-ups. Researchers hope this will change future treatment for asthma and COPD, potentially benefiting over a billion people worldwide.

A new injection for asthma and COPD attacks is 30% more effective than steroid tablets, reducing the need for further treatment. The study, published in The Lancet Respiratory Medicine, found benralizumab, a monoclonal antibody, to be more effective at the point of exacerbation compared to prednisolone. This could be a significant advancement in treating eosinophilic exacerbations, which make up a significant portion of asthma attacks and COPD flare-ups.

Conference on global health and clinical trials addresses bioethics, regulations, patient recruitment, site selection, real-world data, data integration, outsourcing, vendor management, quality in trial conduct, risk-based monitoring, clinical auditing, financial planning, and innovative technologies. Focuses on networking, case studies, presentations, and round tables.

The Global Clinical Trials Connect 2025 conference will discuss futuristic advancements in clinical trials, focusing on innovative strategies, new technologies, and quality collaborations to address increased complexity. Topics include patient recruitment, site selection, real-world data, and risk-based monitoring, among others. The event targets senior-level professionals from pharmaceutical, bio-tech, and CRO companies, offering networking and case study opportunities.

The Global Clinical Trials Connect 2025 conference will discuss futuristic advancements in clinical trials, focusing on innovative strategies, new technologies, and quality collaborations to address increased complexity. Topics include patient recruitment, site selection, data integration, outsourcing, and risk-based monitoring. The event targets senior-level professionals from pharmaceutical, bio-tech, and CRO companies, offering networking and case study presentations.

Scientists explore regenerative therapies to reverse heart damage, including microRNA, drug-induced cell growth, and stem cell grafts, with promising early animal results. Human trials are anticipated, aiming to combat heart disease, the leading cause of death in the US.